This review focuses on the molecular origins of RS in cancer, its impact on DNA damage responses and radiosensitivity, and current therapeutic efforts to exploit replication-stress vulnerabilities—particularly through inhibition of ATR, Chk1, Wee1, and PARP. This evidence concerns the gene PARP1 and cancer.